Michigan Capital Network

PhotoniCare is a medical device company that develops ear-diagnosis devices using light-based technology to see through the eardrum into the middle ear, enabling clinicians to visualize the contents and determine whether antibiotics or surgical interventions are needed. Its flagship device, TOMi Scope, uses near-infrared light to provide views beyond the eardrum and support assessment through optical coherence imaging. The company's imaging platform aims to extend its applications beyond otology and improve clinical decision-making in middle-ear infections. PhotoniCare was founded in 2013 and is based in Champaign, Illinois.

ATLAS Space Operations, Inc. is a company focused on transforming satellite communications and data management. Founded in 2015 and headquartered in Traverse City, Michigan, ATLAS develops the ATLAS Freedom Software Platform, a cloud-based system that enables users to efficiently gather and analyze information from space. This innovative platform features flexible scheduling, cloud processing, and a global network of antennas, allowing clients to optimize their satellite communications at a lower cost. By leveraging advanced technology and a unique approach to space-based communications, ATLAS aims to provide more accessible and scalable solutions for organizations engaged in satellite operations.

ADHD Online provides a formal evaluation for mental health conditions from its licensed psychologist's nationwide network. ADHD Online also provides treatment including medication management, virtual therapy, and other resources. The company was founded in 2018 and is headquartered in Grand Rapids, Michigan.

ONL Therapeutics is a biopharmaceutical company headquartered in Ann Arbor, Michigan, that develops small‑molecule peptide therapeutics to protect photoreceptors and preserve vision. Its pipeline focuses on targeting the FAS apoptotic pathway to prevent photoreceptor loss in retinal diseases such as retinal detachment, aiming to improve surgical outcomes and reduce vision loss. Founded in 2006, the company seeks to bring novel treatments for serious, vision‑threatening retinal conditions.